Lupin’s Generic Bronchoconstriction Medicine Gains FDA Approval
Indian generic drugmaker Lupin got FDA approval for its nebulization-only medicine for long-term maintenance of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
The product — Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 ml, Unit-dose Vials — is a generic equivalent of Brovana Inhalation Solution, 15 mcg/2 ml, made by Sunovion Pharmaceuticals.
Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 ml, Unit-dose Vials are indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Arformoterol Tartrate Inhalation Solution is for use by nebulization only.
According to IQVIA, Brovana had estimated annual sales of $251million in the U.S. in 2021.
About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
February 10, 2022
